RecruitingNot Applicable

Light Exposure on Pain in Hypermobile Ehlers-Danlos Syndrome

United States30 participantsStarted 2022-11-21

Plain-language summary

Chronic pain is a major complaint among many individuals living with hypermobile Ehlers Danlos Syndrome (hEDS) and may have a severe impact on quality of life and activities of daily living. Given the complexity of the disease's pathophysiology, effective treatments are limited. This investigation will examine the impacts of green light exposure on subject-reported pain severity and symptoms. Knowing whether this intervention can improve pain and quality of life in this population may offer valuable guidance to clinicians who treat hEDS patients and to hEDS patients themselves.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 18 years of age or older and able to speak, read, and understand English
✓. Diagnosed with hEDS
✓. Average numeric pain score of 5 out of 10 or greater over the 10 weeks prior to enrolling in the study and failure of medical therapy to control the pain

Exclusion criteria

✕. Initiation of any new analgesic therapy within 30 days of enrollment (note: chronic therapy with a stable regimen maintained for at least 30 days prior to enrollment is permitted)
✕. Serious mental illness, defined as distortions of perception, delusions, hallucinations, and unusual behaviors resulting in loss of contact with reality or Major Depression Disorder
✕. History of color blindness or uncorrected cataracts
✕. Receiving remuneration, or litigation pending, for their medical conditions

What they're measuring

Changes in pain intensity as measured by subject-reported numeric pain severity (NPS) rating

Timeframe: 10 weeks

Trial details

NCT IDNCT05561270

SponsorNew York Institute of Technology

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-11

Contact for this trial

Philip Noto, DO

516.686.4003 pnoto@nyit.edu

View on ClinicalTrials.gov More Ehlers-Danlos Syndrome trials